Ruxolitinib + Azacytidine combination
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-07-01 — Ruxolitinib for the Treatment of Chronic Myelomonocytic Leukemia (CMML): A Phase 2 Expansion: cross-connection with ruxolitinib-cmml: Ruxolitinib + azacytidine is already being tested in MDS/MPN overlap; a dedicated CMML expansion of ruxolitinib monotherapy provides the mechanistic single-agent benchmark for combination rationale. (novelty: 3)
- 2026-03-31 — Ruxolitinib Phosphate and Azacytidine in Treating Patients With Myelofibrosis or Myelodysplastic Syndrome/Myeloproliferative Neoplasm: Phase II trial (trial-early) evaluating ruxolitinib + azacytidine in patients with myelofibrosis or MDS/MPN overlap neoplasms — testing the mechanistic rationale of combining JAK inhibition with hypomethylation in overlap syndromes. (novelty: 3)
Open questions
Related
Contributing findings
Ruxolitinib Phosphate and Azacytidine in Treating Patients With Myelofibrosis or Myelodysplastic Syndrome/Myeloproliferative Neoplasm
31-mar-2026
novelty 3
per-area 3
introduces